Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
13,093,564
-
Shares change
-
-786,859
-
Total reported value, excl. options
-
$273,535,604
-
Value change
-
-$16,382,919
-
Put/Call ratio
-
1.26%
-
Number of buys
-
43
-
Number of sells
-
-37
-
Price
-
$20.91
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q1 2022
109 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2022.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13,093,564 shares
.
Largest 10 shareholders include FMR LLC (4,197,324 shares), Artemis Investment Management LLP (1,428,228 shares), STATE STREET CORP (1,400,753 shares), BlackRock Inc. (1,280,979 shares), VANGUARD GROUP INC (1,059,535 shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (426,177 shares), GEODE CAPITAL MANAGEMENT, LLC (311,587 shares), Rubric Capital Management LP (268,528 shares), MORGAN STANLEY (211,009 shares), and BANK OF AMERICA CORP /DE/ (195,362 shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.